---
title: 2CB7
slug: 2cb7
qid: 
snapshot: enwiki-001366865478
content_hash: 
license: CC BY-SA 4.0
source: https://en.wikipedia.org/w/index.php?oldid=1366865478
tags: [106462793, 106462794, 114646357, 23603337, 26220375, 27236659, 37750075, 50769796, 51480462, 54374437, 63007578, 63697623, 65121943, 67813940, 67819207, 72283819, 90894244]
---

# 2CB7

> [!note] Provenance
> Snapshot `enwiki-001366865478` · content root `…`
> Derived from <https://en.wikipedia.org/w/index.php?oldid=1366865478> · Licensed CC BY-SA 4.0

2CB7, also known as 2C-B-5-hemiFLY-β7, is a serotonin receptor modulator of the phenethylamine, 2C, and benzofuran families related to 2C-B. It is a cyclized phenethylamine or conformationally restrained derivative of 2C-B in which the 5-methoxy group has been cyclized into a dihydrofuran ring and the β position has been connected with the dihydrofuran ring via a propyl group to form a cycloheptane ring to form a tricyclic structure. The compound has syn and anti stereoisomers, with these isomers also being racemic mixtures of (+)- and (–)- enantiomers. The isomers of 2CB7 show affinity for the serotonin 5-HT 2A receptor, with values (K i ) of 74 to 170 nM for syn-2CB7 and 170 to 200 nM for anti-2CB7. These affinities were dramatically lower than those of 2C-B (K i = 0.66–0.88 nM). 2CB7 was first described in the scientific literature by Michael Robert Braden and David E. Nichols and colleagues in 2006. It was developed as part of scientific research into serotonin 5-HT 2A receptor ligand interactions.

2CB7, also known as 2C-B-5-hemiFLY-β7, is a serotonin receptor modulator of the phenethylamine, 2C, and benzofuran families related to 2C-B. It is a cyclized phenethylamine or conformationally restrained derivative of 2C-B in which the 5-methoxy group has been cyclized into a dihydrofuran ring and the β position has been connected with the dihydrofuran ring via a propyl group to form a cycloheptane ring to form a tricyclic structure. The compound has syn and anti stereoisomers, with these isomers also being racemic mixtures of (+)- and (–)- enantiomers. The isomers of 2CB7 show affinity for the serotonin 5-HT 2A receptor, with values (K i ) of 74 to 170 nM for syn-2CB7 and 170 to 200 nM for anti-2CB7. These affinities were dramatically lower than those of 2C-B (K i = 0.66–0.88 nM). 2CB7 was first described in the scientific literature by Michael Robert Braden and David E. Nichols and colleagues in 2006. It was developed as part of scientific research into serotonin 5-HT 2A receptor ligand interactions.
